This is a working overview of evidence gap, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-20. Anything still debated is marked as such rather than presented as settled.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Computed for the free peptide |
| Monoisotopic mass | Approximately 1419 Da | Reported values shift with counterion and hydration |
| Residue count | 15 amino acids | Sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Origin | Fragment of human gastric juice protein | First described in early 1990s research reports |
| Common synonyms | BPC 157; PL 14736; bepecin | Naming varies across papers and catalogues |
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
Fourier-transform ion cyclotron resonance mass spectrometry (also known as Fourier-transform mass spectrometry) is a type of mass spectrometry used for determining the mass-to-charge ratio (m/z) of ions based on the cyclotron frequency of the ions in a fixed magnetic field. The ions are trapped in a Penning trap where they are excited to a larger cyclotron radius by an oscillating electric field perpendicular to the magnetic field. The excitation also results in the ions moving in phase (in a packet). The signal is detected as an image current on a pair of plates which the packet of ions passes close to as they cyclotron. The resulting signal is called a free induction decay (fid), transient or interferogram that consists of a superposition of sine waves. The useful signal is extracted from this data by performing a Fourier transform to give a mass spectrum. Single ions can be investigated in a Penning trap held at a temperature of 4 K. For this the ring electrode is segmented and opposite electrodes are connected to a superconducting coil and the source and the gate of a field-effect transistor. The coil and the parasitic capacitances of the circuit form a LC circuit with a Q of about 50 000. The LC circuit is excited by an external electric pulse. The segmented electrodes couple the motion of the single electron to the LC circuit. Thus the energy in the LC circuit in resonance with the ion slowly oscillates between the many electrons (10000) in the gate of the field effect transistor and the single electron.
== Interactions == There are a few types of medications that interact with valsartan. Combined use with nonsteroidal anti-inflammatory drugs (NSAID) such as naproxen or ibuprofen can result in kidney injury in people who are elderly, dehydrated, or have reduced kidney function. One study conducted Lapi F., et al. found that there was no increased risk of kidney injury when only using either a diuretic or angiotensin receptor blocker with an NSAID but did find an increased risk when all three medications were used together. Valsartan usage with angiotensin receptor blocker, ACE inhibitors, or aliskiren results in additive side effects.
=== April === 2 April – Stand-up comedian Janey Godley wins the inaugural Billy Connolly Spirit of Glasgow Award at the Glasgow International Comedy Festival. 4 April – Data produced by Public Health Scotland indicated that one in three people referred with urgent suspicion of cancer are waiting longer than the target date of 62 days. 5 April – Police arrest former SNP chief executive Peter Murrell as part of their investigation into the party's finances, but release him without charge pending further investigation. 6 April – Following a trial at the High Court in Edinburgh, Kashif Anwar is convicted of the murder of his pregnant wife, Fawziyah Javed, who he pushed from a rocky outcrop on Arthur's Seat, during a holiday in Edinburgh in September 2021. He is sentenced to life imprisonment with a minimum term of 20 years. 7 April BBC News reports that Johnston Carmichael, the accountants who audit the SNP's accounts, have resigned from the role, citing a their decision to do so as having been taken following a review of their clients. The Unite union announces that around 1,300 offshore workers are to stage a 48-hour strike from 24 April over pa, affecting production at dozens of oil and gas platforms. Around 100 workers at Rosyth Dockyard belonging to Unite have voted to strike between 17 April and 10 July in a disagreement with their employers over pay. 8 April – SNP president Mike Russell tells The Herald newspaper he does not think Scottish independence can be achieved "right now", and that the party is facing its biggest crisis for 50 years.
Sources: en.wikipedia.org
== Accords == On February 19, 2015, representatives from the Malian government and the Coordination of Azawad Movements (CMA) agreed upon a new document, including the cessation of hostilities, as negotiations to end the broader war continued in Algiers. On March 1, a mediation agreement was proposed by Algeria, which was accepted by Mali and pro-government militias. The CMA asked for some time to consider the agreement, as there were no propositions for autonomy or federalism for northern Mali, which angered a large portion of Tuareg rebels. The CMA announced their refusal to sign the agreement on April 10. On April 27, the pro-government GATIA and Arab Movement of Azawad (MAA) captured Menaka, initiating new clashes between Tuareg rebels and the pro-government militias. On May 10, the CMA initialized the agreement, but did not sign the text. The peace agreement was signed on May 15 in Bamako by the Malian government, representatives of pro-government militias, and representatives from Algeria, Burkina Faso, Mauritania, Niger, Nigeria, Chad, the African Union, the United Nations, ECOWAS, the Organisation of Islamic Cooperation, the European Union, and France. No CMA representatives were present for the signing on May 15. That same day, fighting broke out near Menaka. Under pressure from international organizations, the CMA finally signed the agreement in Bamako on June 20. The CMA's representative was Sidi Brahim Ould Sidati, a leader of the MAA.
=== Release mechanism === Peptide's release occurs primarily in a calcium-dependent manner through exocytosis of large dense core vesicles in the presynaptic terminal. Big dynorphin immunoreactivity has been detected in regions such as the nucleus accumbens, caudate nucleus, and hippocampus, with significant levels detected in cerebrospinal fluid. The ratio of big dynorphin to dynorphin B in human brain tissue is approximately 1:3.
== Taxonomy == The death cap is named in Latin as such in the correspondence between the English physician Thomas Browne and Christopher Merrett. It was described by French botanist Sébastien Vaillant in 1727, who gave a succinct phrase name "Fungus phalloides, annulatus, sordide virescens, et patulus" (a phallus-shaped, ring-stemmed, dirty green mushroom with a large 'spreading' cap). In 1821, Elias Magnus Fries described it as Agaricus phalloides, but included all white amanitas within its description. Finally, in 1833, Johann Heinrich Friedrich Link settled on the name Amanita phalloides, after Persoon had named it Amanita viridis 30 years earlier. Although Louis Secretan's use of the name A. phalloides predates Link's, it has been rejected for nomenclatural purposes because Secretan's works did not use binomial nomenclature consistently; some taxonomists have, however, disagreed with this opinion. Amanita phalloides is the type species of Amanita section Phalloideae, a group that contains all of the deadly poisonous Amanita species thus far identified. Most notable of these are the species known as destroying angels, including A. virosa, A. bisporigera, A. ocreata, A. verna, and more than a dozen others. The term "destroying angel" has been applied to A. phalloides at times, but "death cap" is by far the most common vernacular name used in English. Other common names also listed include "stinking amanita" and "deadly amanita". A rarely appearing, all-white form was initially described A. phalloides f. alba by Max Britzelmayr, though its status has been unclear.
Sources: en.wikipedia.org
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.
No medicines regulator in the United States or the European Union has approved BPC-157 as a therapeutic product. Presenting it as a drug or as a dietary supplement ingredient would generally not match its regulatory status. Availability as a research chemical does not imply clinical approval.
Published reports rest largely on animal models and cell culture rather than controlled human trials. Review articles describe the proposed mechanisms as incompletely understood. Conclusions about effects in humans therefore remain tentative.
Low temperature slows the chemical reactions, such as oxidation and hydrolysis, that break down a peptide chain. Water and oxygen are the main drivers of degradation, so a cold and dry environment extends usable life. Actual shelf life depends on the batch, the salt form, and the container.